Last updated: October 8, 2026
Impoyz is a niche branded dermatology product containing clobetasol propionate 0.025% cream. The FDA approved it for short-term topical treatment of moderate-to-severe plaque psoriasis in adults. Its commercial position depends on differentiated formulation, dermatology prescribing, reimbursement, and the absence or timing of therapeutically substitutable generic competition.
Public filings do not disclose Impoyz-specific revenue, prescription volume, gross margin, or EBITDA. The product is associated with a privately held specialty-pharmaceutical business rather than a large public company that reports brand-level sales. Its financial trajectory therefore must be assessed through regulatory status, market structure, pricing, channel access, and competitive risk rather than audited product revenue.
What is Impoyz and how is it positioned?
Impoyz contains clobetasol propionate 0.025%, a high-potency topical corticosteroid. It is positioned below the traditional 0.05% clobetasol strength in concentration while retaining high topical potency.
| Attribute |
Impoyz |
| Active ingredient |
Clobetasol propionate |
| Strength |
0.025% |
| Dosage form |
Topical cream |
| FDA application |
NDA 207152 |
| FDA approval |
September 2016 |
| Initial indication |
Moderate-to-severe plaque psoriasis in adults |
| Typical treatment duration |
Up to two consecutive weeks |
| Maximum weekly quantity |
50 grams |
| Commercial category |
Branded prescription dermatology |
| Primary competitors |
Generic clobetasol 0.05%, branded topical corticosteroids, nonsteroidal psoriasis therapies |
| Principal commercial buyer |
Commercial insurers, Medicare Part D plans, specialty pharmacies and retail pharmacies |
The product label limits use because prolonged or excessive topical corticosteroid exposure can cause local and systemic adverse effects. Restrictions include avoiding use on the face, groin and axillae unless directed by a physician, and limiting treatment duration and quantity. These restrictions limit refill frequency and reduce the lifetime revenue opportunity per patient.[1]
When did Impoyz lose regulatory exclusivity?
Impoyz received approval through the FDA new-drug application pathway. Because the product represented a new formulation and strength of an established active ingredient, its commercial protection depended on a combination of regulatory exclusivity, listed patents, formulation differentiation and commercial contracting.
The principal regulatory milestone was the September 2016 approval of NDA 207152. Any applicable three-year new clinical investigation exclusivity would have expired in approximately September 2019, subject to the scope of the exclusivity and the status of any patent listings.[2]
Regulatory exclusivity is separate from patent protection. FDA approval of an abbreviated new drug application does not automatically establish immediate market entry if a listed patent remains enforceable. Conversely, a patent does not prevent an ANDA applicant from challenging validity, enforceability or infringement through a Paragraph IV certification.
Impoyz exclusivity timeline
| Date |
Event |
Commercial significance |
| September 2016 |
FDA approval of NDA 207152 |
Established Impoyz as an approved branded product |
| Approximately September 2019 |
Potential end of three-year regulatory exclusivity |
Reduced the regulatory barrier to follow-on applications |
| Post-2019 |
Continued dependence on patents, formulation differentiation and payer access |
Increased exposure to generic and therapeutic substitution |
| Current market phase |
Mature niche brand |
Growth depends primarily on share capture and reimbursement |
The absence of publicly disclosed product-level sales makes it impossible to quantify the financial effect of exclusivity expiration. The economic effect is nevertheless clear: once regulatory exclusivity ends, the product becomes more exposed to ANDA development and formulary pressure.
What patents protect Impoyz?
Patent protection for Impoyz should be assessed through the FDA Orange Book, USPTO records and litigation dockets. The relevant protection would likely focus on the formulation, vehicle, concentration, delivery characteristics or method of treating psoriasis rather than on clobetasol propionate itself, which is an established active ingredient.
The commercial value of a formulation patent depends on four factors:
- Whether the patent is listed for the approved product.
- Its expiration date and any patent-term adjustment or extension.
- The scope of its claims.
- Whether an ANDA applicant can design around the claims or prevail in a Paragraph IV challenge.
A formulation patent can delay a directly substitutable generic, but it does not eliminate competition from existing clobetasol products. Generic clobetasol propionate 0.05% creams and ointments already provide physicians and payers with lower-cost alternatives in the same therapeutic class.
What formulations are protected by Impoyz?
The commercially important formulation distinction is the 0.025% clobetasol cream. The formulation is designed to provide a high-potency corticosteroid in a cream vehicle suitable for plaque psoriasis treatment. The label does not establish that the product has superior clinical efficacy versus all 0.05% clobetasol products. Its value is therefore more likely to arise from product selection, tolerability, vehicle preference, prescribing convenience and payer positioning.
Formulation patents have limited defensive value when:
- The active ingredient is old.
- The indication is already established.
- Competing topical corticosteroids are widely available.
- Payers treat the products as therapeutically interchangeable.
- Patients can be switched to generic clobetasol or other topical steroids.
How does Impoyz compare with competing psoriasis drugs?
Impoyz competes in a crowded topical psoriasis market rather than in a protected single-product market.
| Product category |
Examples |
Relative commercial position |
| Generic clobetasol |
Clobetasol propionate 0.05% cream, ointment and solution |
Lowest-cost direct potency competitor |
| Branded high-potency steroids |
Several branded corticosteroid products |
Compete on vehicle, brand and contracting |
| Vitamin D analog combinations |
Calcipotriene/betamethasone products |
Compete through combination therapy and guideline use |
| Nonsteroidal topicals |
Tapinarof, roflumilast, crisaborole and related products |
Compete on chronic-use profile and steroid avoidance |
| Systemic and biologic therapies |
Oral immunomodulators and biologics |
Used for broader or more severe disease |
| Impoyz |
Clobetasol propionate 0.025% cream |
Niche branded option within topical high-potency treatment |
Impoyz has a narrower commercial value proposition than newer nonsteroidal psoriasis products. Nonsteroidal therapies can be used for longer treatment periods in certain populations and may avoid some corticosteroid-related restrictions. Their disadvantages include higher acquisition cost, prior authorization and payer step edits.
Impoyz can retain demand where dermatologists prefer a familiar corticosteroid product, where the cream vehicle fits patient preference, or where the product has favorable formulary placement.
What is the FDA regulatory status of Impoyz?
Impoyz is an FDA-approved prescription product, not an over-the-counter medicine or biologic. It is regulated as a topical small-molecule drug. The product does not carry biosimilar risk because biosimilars apply to biological products, not clobetasol propionate cream.[1]
The main regulatory risks are therefore:
- ANDA approval for a therapeutically equivalent generic.
- Patent litigation following a Paragraph IV certification.
- Manufacturing or quality failures.
- Labeling changes related to corticosteroid safety.
- Payer restrictions that reduce utilization despite continued FDA approval.
A generic applicant would generally seek approval through the ANDA pathway and demonstrate pharmaceutical equivalence, bioequivalence or otherwise applicable product-specific requirements. FDA approval would allow substitution under state pharmacy laws if the generic receives an AB rating.
Which companies are challenging Impoyz?
No publicly established, high-profile Paragraph IV litigation campaign against Impoyz is evident in the core public record used for this assessment. That does not establish that no ANDA has been filed. ANDA litigation can remain difficult to identify before a complaint is filed, and private label, contract manufacturing or licensing arrangements can obscure the commercial identity of an applicant.
The most credible competitive threat is conventional generic development rather than biosimilar entry. Generic companies with topical dermatology capabilities can compete through:
- Clobetasol 0.05% products.
- A potential 0.025% equivalent.
- Other high-potency corticosteroid formulations.
- Private-label products sold through pharmacy and payer channels.
A Paragraph IV challenge would have the greatest impact if it targeted the core formulation or the only commercially meaningful patent protection. A successful challenge could accelerate entry. A settlement could delay entry while preserving the brand’s near-term cash flow, but no public settlement should be assumed without a filed agreement or court record.
How strong is the Impoyz patent estate?
The patent estate appears strategically narrower than the estates surrounding novel active ingredients or biologics. Clobetasol propionate is an old molecule, so the defensible value must come from formulation, manufacturing, delivery or use claims.
Patent strength is likely moderate to weak in commercial terms unless the estate has claims that are difficult to design around. The product remains exposed to:
- Generic substitution from other clobetasol strengths.
- Non-infringing alternative vehicles.
- Payer preference for lower-cost corticosteroids.
- Limited treatment duration under the label.
- Low switching costs for physicians and pharmacies.
A strong patent estate would require broad, valid claims covering the commercially important formulation and a remaining term long enough to support investment in sales promotion. A narrow formulation patent can protect a product technically while failing to protect its broader therapeutic market.
What is the financial trajectory for Impoyz?
Impoyz likely follows the financial profile of a niche specialty brand:
- Initial launch investment in dermatology sales, sampling and payer access.
- Early growth through physician awareness and formulary contracting.
- Margin compression as payers demand rebates and cheaper alternatives.
- Maturing revenue as refill volume stabilizes.
- Downside risk from generic entry or reduced promotional spending.
Product-level revenue is not publicly reported. The private ownership structure prevents direct analysis of annual sales, prescription growth, net price, gross-to-net deductions or contribution margin. The absence of disclosed revenue should not be interpreted as evidence of either commercial failure or material scale.
The most important financial variables are:
| Variable |
Likely effect on Impoyz |
| Average net price |
Determines revenue quality after rebates and discounts |
| Formulary tier |
Controls patient access and abandonment |
| Prior authorization |
Can reduce prescription conversion |
| Generic clobetasol pricing |
Creates direct payer pressure |
| Dermatology sales force |
Supports prescribing but raises fixed costs |
| Sampling |
Can drive trial while weakening initial paid demand |
| Patent duration |
Determines the period available to recover launch investment |
| Patient treatment duration |
Limits refill volume |
| Wholesale acquisition cost |
Influences payer negotiations and gross-to-net erosion |
The product’s revenue ceiling is constrained by the nature of topical steroid treatment. Physicians generally prescribe limited courses rather than indefinite maintenance therapy. A brand can achieve strong prescription volume without generating the recurring revenue profile associated with chronic systemic medicines or biologics.
What generic launch risks exist for Impoyz?
The highest-probability downside scenario is gradual erosion rather than an immediate collapse. Physicians may continue prescribing Impoyz for selected patients while plans move new prescriptions toward lower-cost alternatives.
Generic entry scenarios
| Scenario |
Market outcome |
Financial effect |
| No directly substitutable generic |
Brand retains niche pricing, subject to payer pressure |
Stable but limited growth |
| One generic entrant |
Payers obtain leverage; selective substitution begins |
Moderate net-price and volume erosion |
| Multiple generic entrants |
Price competition accelerates |
Significant revenue decline |
| Successful Paragraph IV challenge |
Earlier-than-expected entry |
Sharp reduction in value |
| Patent settlement with delayed entry |
Brand retains temporary protection |
More predictable but finite cash flow |
| Therapeutic substitution |
Newer nonsteroidal products gain share |
Long-term erosion without generic entry |
Generic risk is higher because the active ingredient is established and the clinical market has many alternatives. A 0.025% generic would create the most direct substitution risk, but 0.05% clobetasol and other potent corticosteroids already limit pricing power.
What licensing deals and commercial partnerships affect Impoyz?
Publicly available information does not establish a major transaction that would allow Impoyz revenue to be analyzed through a large pharmaceutical parent’s financial statements. The product’s economics are more consistent with a specialty-pharma commercialization model involving outsourced manufacturing, dermatology promotion and pharmacy distribution.
Any licensing arrangement would be commercially important if it transferred:
- NDA ownership.
- Orange Book-listed patent rights.
- Manufacturing rights.
- Promotion responsibility.
- Geographic commercialization rights.
- Royalty or milestone obligations.
Without disclosed contract terms, licensing economics cannot be incorporated into a reliable product valuation. The key diligence issue is whether the commercial entity controls the NDA, the formulation intellectual property and the supply chain, or merely holds promotional rights.
What geographic markets does Impoyz address?
Impoyz’s principal commercial opportunity is the United States, where the product has FDA approval and can participate in the U.S. prescription dermatology market. U.S. value is concentrated in commercial insurance and Medicare Part D access, with pharmacy benefit managers influencing reimbursement.
International expansion would require separate regulatory approvals, local pricing decisions and distribution arrangements. A product-specific global opportunity cannot be inferred from U.S. approval because topical corticosteroid markets are highly sensitive to local reimbursement, generic penetration and national prescribing practice.
Key Takeaways
- Impoyz is a branded clobetasol propionate 0.025% cream approved by the FDA in September 2016.
- Its main commercial differentiation is formulation and strength, not a novel active ingredient.
- Product-level revenue and profitability are not publicly disclosed.
- Regulatory exclusivity from the original approval would not be the primary barrier to entry today.
- Patent value depends on formulation and related claims, with Orange Book status controlling the practical analysis.
- Biosimilar risk is not applicable because Impoyz is a small-molecule topical drug.
- Generic clobetasol 0.05% products already create substantial pricing and substitution pressure.
- The likely financial profile is a small specialty brand with limited refill frequency, payer sensitivity and meaningful downside from direct generic entry.
- The strongest commercial defenses are formulary access, dermatologist loyalty, supply reliability and a patent estate that is difficult to design around.
FAQs About Impoyz Market and Financial Outlook
Is Impoyz a generic or a brand-name drug?
Impoyz is a branded prescription drug. It contains the established active ingredient clobetasol propionate at a 0.025% concentration.
Does Impoyz have biosimilar competition?
No. Biosimilars compete with biologic medicines. Impoyz is a topical small-molecule drug, so any follow-on competition would come through generic or therapeutically substitutable products.
How long can patients use Impoyz?
The FDA label limits treatment to short-term use, generally up to two consecutive weeks, with a maximum quantity of 50 grams per week. Individual treatment decisions remain subject to the prescribing physician and the product label.[1]
Is clobetasol 0.05% a substitute for Impoyz?
It can be a therapeutic alternative, but it is not automatically an identical substitute. Physicians and payers may compare potency, vehicle, concentration, indication, formulary status and patient response.
What would most increase Impoyz’s commercial value?
The largest value drivers would be durable patent protection, broad payer coverage, low patient abandonment, reliable manufacturing and evidence that the formulation provides a meaningful clinical or adherence advantage over lower-cost clobetasol products.
References
- U.S. Food and Drug Administration. (2016). Impoyz (clobetasol propionate) cream, 0.025% prescribing information. Drugs@FDA.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and generic drug approval standards. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug product database. Drugs@FDA.
